Cathie Wood ARK Investment Management
Cathie Wood is the founder, CEO, and CIO of ARK Investment Management, an investment firm known for its focus on “disruptive innovation”. She gained widespread attention for her bold market calls and high conviction in cutting-edge technologies such as electric vehicles, genomics, and blockchain. Under her guidance, ARK’s exchange-traded funds (ETFs) attracted substantial interest from both retail and institutional investors. Wood’s investment philosophy emphasizes research-driven analysis and long-term growth potential, positioning her as one of today’s most influential voices in the world of finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$103M |
| 2 |
Coinbase
COIN
|
+$77.6M |
| 3 |
Ginkgo Bioworks
DNA
|
+$40.4M |
| 4 |
Twilio
TWLO
|
+$33.2M |
| 5 |
Prime Medicine
PRME
|
+$29.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fate Therapeutics
FATE
|
+$140M |
| 2 |
NVIDIA
NVDA
|
+$126M |
| 3 |
Spotify
SPOT
|
+$62.8M |
| 4 |
EXAS
Exact Sciences
EXAS
|
+$62.2M |
| 5 |
SGFY
Signify Health, Inc.
SGFY
|
+$61.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 37.56% |
| 2 | Technology | 34.23% |
| 3 | Consumer Discretionary | 8.65% |
| 4 | Communication Services | 7.7% |
| 5 | Financials | 5.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VERV
26
DELISTED
Verve Therapeutics
VERV
| $84.5M | 0.73% |
4,365,830
+971,971
| +29% | +$25.8M |
|
27
Kratos Defense & Security Solutions
KTOS
$10.7B
| $80M | 0.69% |
7,748,357
-441,287
| -5% | -$4.39M |
|
28
Iridium Communications
IRDM
$5.19B
| $76.8M | 0.67% |
1,494,455
-274,325
| -16% | -$13.8M |
|
|
29
NVIDIA
NVDA
$5.2T
| $76.5M | 0.66% |
5,231,810
-8,594,430
| -62% | -$126M |
|
30
Incyte
INCY
$25.9B
| $76.3M | 0.66% |
950,393
-79,796
| -8% | -$6.11M |
|
31
Schrodinger
SDGR
$1.47B
| $72M | 0.62% |
3,852,037
+87,330
| +2% | +$1.81M |
|
32
CareDx
CDNA
$2.51B
| $70.6M | 0.61% |
6,188,182
+401,062
| +7% | +$5.94M |
|
33
Adaptive Biotechnologies
ADPT
$4.15B
| $70.3M | 0.61% |
9,201,245
-135,374
| -1% | -$1.05M |
|
34
Deere & Co
DE
$175B
| $64.4M | 0.56% |
150,253
-26,415
| -15% | -$10.7M |
|
35
Mercado Libre
MELI
$97.5B
| $64.3M | 0.56% |
75,982
-13,298
| -15% | -$11.8M |
|
36
Cerus
CERS
$566M
| $57.9M | 0.5% |
15,863,384
-990,491
| -6% | -$3.73M |
|
|
TWOU
37
DELISTED
2U Inc
TWOU
| $57.5M | 0.5% |
305,534
-8,223
| -3% | -$1.63M |
|
38
AeroVironment
AVAV
$8.14B
| $55.2M | 0.48% |
644,045
-106,146
| -14% | -$9.08M |
|
|
NVTA
39
DELISTED
Invitae Corporation
NVTA
| $50.4M | 0.44% |
27,072,844
-3,395,537
| -11% | -$8.29M |
|
40
Teradyne
TER
$58.7B
| $48.5M | 0.42% |
555,038
+2,720
| +0.5% | +$233K |
|
|
41
Fate Therapeutics
FATE
$279M
| $42.5M | 0.37% |
4,214,863
-7,440,970
| -64% | -$140M |
|
|
ACCD
42
DELISTED
Accolade Inc
ACCD
| $42.5M | 0.37% |
5,458,916
-459,449
| -8% | -$4.39M |
|
|
RPTX
43
DELISTED
Repare Therapeutics
RPTX
| $35.7M | 0.31% |
2,428,055
-203,973
| -8% | -$3.05M |
|
44
Vertex Pharmaceuticals
VRTX
$139B
| $35.3M | 0.31% |
122,197
-35,248
| -22% | -$10.7M |
|
45
Arcturus Therapeutics
ARCT
$382M
| $34.1M | 0.3% |
2,012,429
-169,274
| -8% | -$2.95M |
|
46
Veeva Systems
VEEV
$40.3B
| $34.1M | 0.3% |
211,478
-17,722
| -8% | -$3.03M |
|
|
MTLS
47
Materialise
MTLS
$382M
| $31.6M | 0.27% |
3,592,979
-2,269,019
| -39% | -$22.5M |
|
|
48
Prime Medicine
PRME
$615M
| $30.5M | 0.26% |
+1,639,984
| New | +$29.6M |
|
49
monday.com
MNDY
$3.84B
| $30.4M | 0.26% |
249,493
-12,256
| -5% | -$1.27M |
|
50
908 Devices
MASS
$441M
| $28.1M | 0.24% |
3,689,475
-85,719
| -2% | -$1.04M |
|
Similar funds
Cathie Wood's Q4 2022 Portfolio in Review
As of Q4 2022, Cathie Wood held 255 positions worth $11.5B, down 20% from $14.3B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Cathie Wood withdrew a net $790M in Q4 2022, closing 23 positions and reducing 163 holdings. Its most notable exit was Signify Health, Inc., an estimated $61.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 38% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Cathie Wood opened a new position in Prime Medicine worth $30.5M.
- Cathie Wood's largest Q4 2022 buy was Prime Medicine: 1,639,984 shares worth $30.5M.
- Cathie Wood added most to Tesla in Q4 2022, an estimated $103M increase.
- Cathie Wood's biggest Q4 2022 reduction was Fate Therapeutics, cutting an estimated $140M.
- Cathie Wood fully exited Signify Health, Inc. in Q4 2022, selling an estimated $61.1M.
- Cathie Wood's ten largest holdings make up 46% of its $11.5B portfolio in Q4 2022.
- Cathie Wood opened 5 new positions and closed 23 in Q4 2022.
- Cathie Wood's portfolio value fell 20% quarter-over-quarter to $11.5B.
Based on ARK Investment Management's 13F filing for Q4 2022, filed 24 Jan 2023.